Dr. Vince Clinical Research Announces First Dosing in Atopic Dermatitis Patients with Enveda’s First-in-Class Investigational Drug ENV-294

News > Health News

Audio By Carbonatix

6:00 AM on Tuesday, September 16

The Associated Press

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Sep 16, 2025--

Dr. Vince Clinical Research (DVCR), a full-service contract research organization (CRO) specializing in early phase and multi-site clinical trials, announces that the first subject has been dosed in a Phase 1b multi-site study evaluating ENV-294, Enveda’s first-in-class anti-inflammatory drug candidate in adults with moderate to severe atopic dermatitis (AD).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916277343/en/

Dr. Vince Clinical Research, located at 7401 W. 91st Street, Overland Park, KS 66212.

ENV-294 is a first-in-class small molecule developed using Enveda’s proprietary drug discovery platform. It is designed to address atopic dermatitis and other chronic inflammatory diseases through a differentiated mechanism of action. ENV-294 demonstrates the potential to address unmet needs in moderate to severe AD patients who require systemic therapies but may not respond well to or tolerate currently available treatments.

“DVCR has been an exceptional partner in supporting the advancement of our investigational drug, ENV-294, into the clinic,” said José Trevejo, MD, PhD, Chief Medical Officer and Head of Clinical Pipeline Strategy at Enveda. “Their deep operational expertise and collaborative approach were instrumental in the successful completion with promising data from our first-in-human study. We look forward to continuing this productive relationship as we progress through early clinical development.”

This Phase 1b study follows a successful Phase 1a trial, also conducted by DVCR, which was a randomized, double-blind, placebo-controlled, single and multiple ascending dose study in healthy adults. ENV-294 was well-tolerated across all dose levels, with no dose-limiting toxicities or serious adverse events and demonstrated a favorable safety, tolerability and pharmacokinetic profile. The multi-site Phase 1b study is designed to build upon those results by assessing ENV-294’s safety, tolerability, pharmacodynamics, target engagement and preliminary efficacy.

“This important milestone, dosing the first subject with atopic dermatitis in the Phase 1b study, is a true testament to the scientific expertise and transformative work of the Enveda team,” said Dr. Brad Vince, CEO and Chief Medical Officer of DVCR. “We are honored that Enveda selected DVCR as a preferred partner for this important program.”

According to the National Eczema Association, atopic dermatitis affects over 26 million Americans and approximately 200 million people worldwide. The condition is characterized by chronic, relapsing inflammation of the skin and is often associated with significant itch, skin pain and impaired quality of life.

About Dr. Vince Clinical Research

Dr. Vince Clinical Research (DVCR) is a full-service contract research organization (CRO) specializing in early phase trials in both healthy normal volunteers and patient populations across a wide range of trial designs and therapeutic areas such as neuroscience, substance abuse, pain, cardiometabolic disorders, infectious diseases and many others. CRO services include project management, data management, biostatistics, statistical programming, PK/PD analysis, clinical and medical monitoring, medical writing as well as site feasibility and management for multi-site trials with our global network of site partners. Additionally, DVCR operates one of the most innovative and technologically advanced clinical pharmacology units in the world with over 90 beds for overnight confinement, a cGMP compliant pharmacy as well as luxurious amenities to support diverse study participant recruitment and retention. By leveraging technology and one of the country’s most experienced leadership teams in early clinical development, DVCR provides Smarter Faster Data ® to its biopharmaceutical clients.

For more information, visit:https://drvince.com/cro

Connect with DVCR onLinkedIn and YouTube

View source version on businesswire.com:https://www.businesswire.com/news/home/20250916277343/en/

CONTACT: Media Contact:

Laura Harding

Vice President, Marketing

Dr. Vince Clinical Research

913-333-3000

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA KANSAS

INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS RESEARCH PHARMACEUTICAL SCIENCE BIOTECHNOLOGY

SOURCE: Dr. Vince Clinical Research